Search

Your search keyword '"Schönlein, Martin"' showing total 204 results

Search Constraints

Start Over You searched for: Author "Schönlein, Martin" Remove constraint Author: "Schönlein, Martin"
204 results on '"Schönlein, Martin"'

Search Results

1. Cancer cells impair monocyte-mediated T cell stimulation to evade immunity

2. Correction: Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

3. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

4. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey

5. Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab

6. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

7. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

8. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

9. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

10. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

11. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

12. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer

13. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

14. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

15. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

16. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

17. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

18. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

19. Virus-induced senescence is a driver and therapeutic target in COVID-19

20. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

21. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022

22. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

23. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction

24. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

25. Peripheral and portal venous KRAS ctDNA detection as independent prognostic markers of early tumour recurrence in pancreatic ductal adenocarcinoma

26. Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study

27. Age, Successive Waves, Immunization, and Mortality in Elderly COVID-19 Haematological Patients: EPICOVIDEHA Findings

28. S292: NIRMATRELVIR/RITONAVIR IN COVID-19 PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES: A REPORT FROMTHE EPICOVIDEHA REGISTRY

29. P429: THERAPY-INDUCED SENESCENCE TRIGGERS UPREGULATION OF ANTIGEN PRESENTATION VIA PRC2 INHIBITION AND PROMOTES ANTI-TUMOUR IMMUNITY IN ACUTE MYELOID LEUKAEMIA

30. P1521: IMPROVED CLINICAL OUTCOME OF COVID-19 IN HAEMATOLOGIC MALIGNANCY PATIENTS RECEIVING A FOURTH DOSE OF ANTI-SARS-COV-2 VACCINE: AN EPICOVIDEHA REPORT

31. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey.

32. COVID-19 in adult acute myeloid leukemia patients:a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)

33. Outcome of COVID-19 in allogeneic stem cell transplant recipients:Results from the EPICOVIDEHA registry

34. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19:matched-paired analysis in the EPICOVIDEHA registry

35. Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry

36. COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)

37. COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA)

38. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

39. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

40. Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry

41. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

42. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

47. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

48. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers in unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo-bev).

49. Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry

50. Peripheral and Portal VenousKRASctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma

Catalog

Books, media, physical & digital resources